Before recommending semaglutide, tirzepatide, or another medically supervised weight-loss strategy, a physician may review weight history, prior weight-loss attempts, BMI, waist circumference, body composition goals, A1C, fasting glucose, insulin-resistance risk, cholesterol, triglycerides, blood pressure, liver enzymes, fatty liver risk, kidney function, current medications, diabetes medication use, history of pancreatitis, gallbladder disease, gastrointestinal symptoms, thyroid history, protein intake, exercise habits, sleep quality, hormonal symptoms, inflammation-related concerns, side-effect tolerance, and long-term maintenance planning
Bergenstal RM, Peyrot M, Dreon DM et al (2019) Implementation of basal-bolus therapy in type 2 diabetes: a randomized controlled trial comparing bolus insulin delivery using an insulin patch with an insulin pen
Table 1 outlines these comparisons further
A randomized controlled trial [J]
A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects